NVIDIA Releases RFD4-Proteina Open Model for Protein Design, Claims Higher Success Rates Than Baselines
NVIDIA launches RFD4-Proteina to accelerate drug discovery and partners with Siemens Healthineers on adaptive radiotherapy, showcasing AI's expansion into life sciences.
NVIDIA announced at GTC Berlin on October 21, 2026, that it has debuted RFD4-Proteina, a new open-source model developed in collaboration with the University of Washington Medicine Institute for Protein Design. The model combines programmable protein design with search capabilities to help scientists navigate vast biological design spaces more efficiently.
According to research drafts cited in NVIDIA's press release, RFD4-Proteina achieved higher computational design success rates and generation throughput than evaluated baselines across four benchmark suites: protein binding, small-molecule binding, enzyme scaffolding, and DNA binding. These performance metrics are currently self-reported by the vendor and have not been independently reproduced. The model is available through partners including Amazon Bio Discovery, Anthropic’s Claude Science, Hugging Face, and others.
Beyond drug discovery, NVIDIA also announced a collaboration with German medical technology company Siemens Healthineers to develop next-generation adaptive radiotherapy systems. By leveraging Nemotron foundation models and CUDA-accelerated computing, the project aims to use agentic co-planning and real-time simulation to improve treatment precision and address specialist capacity constraints in cancer care.
For AI industry investors, this move signals NVIDIA's strategy to extend its hardware dominance into high-barrier vertical markets like life sciences. By providing specialized open models and platform tools, NVIDIA seeks to lock in long-term compute demand from research institutions and pharmaceutical companies, although the near-term financial contribution of these applications remains uncertain.